GlobeNewswire 10/30/2019 David Eatwell to Retire as Chief Financial Officer of Genmab

GlobeNewswire 10/18/2019 CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide a...

GlobeNewswire 10/15/2019 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

GlobeNewswire 9/26/2019 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalid...

GlobeNewswire 9/13/2019 Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carf...

GlobeNewswire 9/13/2019 Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsin...

GlobeNewswire 9/9/2019 Genmab and Tempus Enter into Strategic Collaboration Agreement

GlobeNewswire 8/30/2019 Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Scle...

GlobeNewswire 8/22/2019 Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan

GlobeNewswire 8/14/2019 Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance

GlobeNewswire 7/23/2019 Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Deposit...

GlobeNewswire 7/22/2019 Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) ...

GlobeNewswire 7/19/2019 Major Shareholder Announcement

GlobeNewswire 7/19/2019 Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering

GlobeNewswire 7/18/2019 Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States

GlobeNewswire 7/16/2019 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019

GlobeNewswire 7/12/2019 Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulatio...

GlobeNewswire 7/9/2019 Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States

GlobeNewswire 7/8/2019 Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newl...

GlobeNewswire 6/27/2019 Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and D...

GlobeNewswire 6/25/2019 Major Shareholder Announcement

GlobeNewswire 6/19/2019 Major Shareholder Announcement

GlobeNewswire 6/11/2019 Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

GlobeNewswire 5/30/2019 U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexa...